US Edition
Toripalimab, Bevacizumab, and Irinotecan in dMMR/MSI Locally Advanced Colorectal Cancer: First-Stage Results from a Phase Ib/II Trial
Summary by Stemwell Science News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Toripalimab, Bevacizumab, and Irinotecan in dMMR/MSI Locally Advanced Colorectal Cancer: First-Stage Results from a Phase Ib/II Trial
This was the first stage of the Phase Ib/II trial evaluating the effectiveness and safety of toripalimab, irinotecan, and bevacizumab in patients with rectal cancer refusing up-front surgery or radiation therapy and patients with T4NanyM0 colon cancer with deficiency of mismatch repair or microsatellite instability. [Cell Reports Medicine] Full ArticleGraphical Abstract
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
